The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | BVd versus DVd in R/R multiple myeloma: findings from the DREAMM-7 trial
Vania Hungria, MD, PhD, Santa Casa Medical School and Clinica São Germano, São Paulo, Brazil, comments on the results of the Phase III DREAMM-7 trial (NCT04246047), which compared belantamab mafodotin plus bortezomib and dexamethasone (BVd) to daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory (R/R) multiple myeloma. The overall survival is predicted to be higher in the BVd arm, with double the duration of response. This new combination offers robust efficacy, manageable safety, and easy administration, potentially establishing it as a new standard of care for patients with R/R multiple myeloma. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Today I’d like to talk about the DREAMM-7 study. DREAMM-7 is a clinical trial. In this trial we compared a new drug, belantamab mafodotin, in combination with bortezomib and dexamethasone versus daratumumab, bortezomib, and dexamethasone. This study we have the first analysis and in the first analysis we met the endpoint progression-free survival and now in this meeting we present the updates in overall survival and we have the result and the overall survival is very… the curve, the Kaplan-Meier curve is very interesting because the discovery has early separation, sustained, and the hazard ratio was 0...
Today I’d like to talk about the DREAMM-7 study. DREAMM-7 is a clinical trial. In this trial we compared a new drug, belantamab mafodotin, in combination with bortezomib and dexamethasone versus daratumumab, bortezomib, and dexamethasone. This study we have the first analysis and in the first analysis we met the endpoint progression-free survival and now in this meeting we present the updates in overall survival and we have the result and the overall survival is very… the curve, the Kaplan-Meier curve is very interesting because the discovery has early separation, sustained, and the hazard ratio was 0.58. And the median overall survival was not reached, but with a simulation was calculated the predicted overall survival and the overall survival was 84 months for bela-Vd and 51 months for dara-Vd. And besides this data we have another PFS2 and the PFS2 was very interesting because in the bela-Vd arm was not reached and in BVd arm is 33 months. And the duration of response was the double for the bela-Vd. And it’s interesting too because MRD negativity in the first analysis was not statistically significant. But now with this data with overall survival included the MRD negativity now is statistically different so now we have a new combination with the belamaf plus bortezomib and dex with a very robust efficacy, a manageable safety, and the easy administration, I think we can, we have a new standard of care for patients in relapse and refractory multiple myeloma, in first relapse and later.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AbbVie: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer and Regeneron: Honoraria, Speakers Bureau; GSK: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Johnson & Johnson: Honoraria; Takeda: Honoraria, Membership on an entity’s Board of Directors or advisory committees.
